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SynoviocyteAngiogenesis in rheumatoid arthritis (RA) is one of the histological hallmarks, which is mediated by expression of
vascular endothelial growth factor (VEGF) in RA synovium. VEGF expression is enhanced by TNF-α, the main
pro-inﬂammatory cytokine in RA. B cell activating factor (BAFF) which plays a role in maturation andmaintenance
of B cells is also associated with autoimmune RA. Here, we investigated whether BAFF could regulate VEGF expres-
sion in TNF-α-stimulated synovium usingMH7A synovial cells that are established by transfection with the SV40 T
antigen. Changes in hBAFF and hVEGF were measured by western blotting, RT-PCR and luciferase promoter assay.
When MH7A cells were treated with TNF-α, we observed that TNF-α increased the expression of hBAFF and
hVEGF. TNF-α also increased transcriptional activity of hBAFF and hVEGF as judged by luciferase promoter assay. In-
hibition of hBAFF expression with BAFF–siRNA decreased transcriptional level and activity of hVEGF. In addition,
when c-fos expressionwas inhibited by the transfectionofMH7Acellswith c-fos-siRNA, data showed that transcrip-
tional level and activity of both hBAFF and hVEGF were attenuated by the activation with TNF-α. Our results dem-
onstrate for the ﬁrst time that VEGF-mediated angiogenesis in RA could be controlled by TNF-α-induced BAFF
expression through c-Fos. Data suggest that TNF-α-induced BAFF expression and BAFF-mediated VEGF expression
in synovium may cooperate to maintain the capacity of such cells to protect B cells from apoptosis and the supply
of nutrients and oxygen in inﬂammatory microenvironments.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA), chronic inﬂammatory autoimmune
joint disease, is characterized by histological hallmarks such as hyper-
plasia of the synovial lining cells, mononuclear cell inﬁltration, angio-
genesis, and cartilage and osteoclastic bone destruction [1–3].
Fibroblast-like synoviocytes (FLSs) in RA synovium develop the ap-
pearance of “transformed cells” under the regulation of cell cycle. Abun-
dant pro-inﬂammatory cytokines such as IL-1, IL-6 and TNF-α are able
to induce cartilage destruction through the production of destructive en-
zymes from RA-FLS [4,5]. Vascular endothelial growth factor (VEGF) ex-
pression is also enhanced by pro-inﬂammatory cytokines [2,6] and it ledast-like synoviocytes; BAFF, B
or necrosis factor; ROS, Reac-
ular endothelial growth factor.
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.V. Open access under CC BY-NC-ND lto the increase in new blood vessel formation (=angiogenesis) of RA
synovium [2,7]. Angiogenesis is highly active particularly during the
onset of the disease [8]. Newly formed blood vessels can transport inﬂam-
matory cells to synovitis sites and supply nutrients and oxygen to main-
tain a chronic inﬂammatory state [2].
BAFF plays a role in B cell maturation and the maintenance.
Biological role of BAFF is mediated by the speciﬁc receptors, B-cell
maturation antigen (BCMA), transmembrane activator and calcium
modulator and cyclophilin ligand interactor (TACI) and BAFF receptor
(BAFF-R) [9,10]. BAFF is associated with autoimmune disorders and
induces rheumatic arthritis [11,12]. In our previous studies, BAFF level
was also increased inmousemodel of allergic asthma [13], and systemic
lupus erythematosus (SLE) [14].
BAFF is produced by macrophages or dendritic cells (DCs) upon stim-
ulationwith lipopolysaccharide (LPS) or interferon (IFN)-γ [9,10]. BAFF is
produced not only by myeloid cells, but also by non-lymphoid cell types
[15–17] including mucosal epithelial cells in the respiratory tract [16],
human intestinal epithelial cells [18], salivary gland [15] in response to
IFNs, and RA-FLS [19,20]. However, little has been known about the link-
age of BAFF to VEGF-mediated angiogenesis in FLS.
BAFF gene expression was in part regulated by reactive oxygen
species generated by LPS [21] but it was controlled by TLR4- oricense.
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was supported by NF-κB activation as judged by reduced IκB degrada-
tion and increased nuclear translocation of p65/RelA [21]. Cellular
co-activators such as CBP (CREB-binding protein)/p300 [23,24] were
also involved in BAFF promoter activation [25]. BAFF expression was
up-regulated by LPS-induced cAMP production through PKA-mediated
CREB and Epac1-mediated Rap1 activation [26,27]. JAK/STAT signaling
pathways regulated BAFF expression in human intestinal epithelial
cells [18]. In addition, protein kinase C (PKC) stimulates human BAFF
expression through ROS-dependent c-Fos in THP-1 pro-monocytic
cells [28]. These reports demonstrate that BAFF gene in various cell
types could be expressed by the different transcriptional regulations.
However, little has been known about what transcriptional regulations
are involved in BAFF gene expression from RA-FLS.
Here, we investigated whether VEGF expression could be associated
with BAFF gene expression and it could be mediated by transcription
factor, c-Fos, a component of AP-1 protein using MH7A synovial cell
line. Our data demonstrate that TNF-α-induced BAFF expression
and BAFF-mediated VEGF expression may cooperate through c-Fos
in FLS. It suggests that VEGF-mediated angiogenesis in RA could
be controlled by TNF-α-induced BAFF expression in inﬂammatory
microenvironments.
2. Materials and methods
2.1. Reagents
TNF-α was purchased from R&D Systems Inc. (Minneapolis, MN).
Small interference RNA for BAFF and c-fos was purchased from Bioneer
Inc. (Daejeon, Korea). Except where indicated, all other materials are
obtained from the Sigma Chemical Company (St. Louis, MO).
2.2. Collection of human RA-FLS
Informed consent was obtained from all patients, and the experi-
mental protocol was approved by the Konkuk University Medical
Center Institutional Review Board. RA patients fulﬁlled the criteria
of the American College of Rheumatology (formerly, the American
Rheumatism Association) [29]. RA FLSwere isolated from the synovial
tissues according to a protocol as follows. Brieﬂy, synovial tissues
were washed thoroughly with RPMI 1640 (Gibco BRL, Gaithersburg,
MD), minced into 1 mm3, and digested for 90 min at 37 °C in RPMI
1640 containing 1 mg/ml collagenase (Gibco BRL). The digested tissue
was ﬁltered with a 70 μm cell strainer (Becton Dickinson, Franklin
Lakes, NJ), and centrifuged at 250 ×g for 10 min. The cell pellet was
resuspended in RPMI 1640, washed 3 times by centrifugation, and
suspended inα-minimum essential medium (α-MEM; Irvine Scientiﬁc,
Santa Ana, CA) containing 10% fetal bovine serum (FBS) (Gibco BRL).
The cells were then subcultured for 3–6 passages before use.
2.3. Cloning hBAFF gene promoter
Human BAFF (hBAFF) promoter (1 kb) upstream (AF116456.1)
from the starting codon (ATG) was searched from NCBI database
(AL157762.13). Primers for various sizes of hBAFF promoter were
designed from the sequence; forward primer including SacI site (gag
ctc cga cct gtt agg ctg t for 1 kb; gga gct ctt ttc ctt aaa aat ata ttc for
0.75 kb; gag ctc att aat tat ttt tat gac ag c for 0.5 kb and gag ctc tga
aag tga aat gag gaa gac for 0.25 kb) and reverse primer including
BglII site (gga gat cta tca cta ctt gaa ctt tga agg for all size of pro-
moters). Each size of upstream sequence was ampliﬁed from human
peripheral blood mononuclear cell's chromosomal DNA by PCR. Each
promoter was cloned into the site between SacI and BglII of pGL3
plasmid that containsﬁreﬂy luciferase (pGL3-hBAFF-Luc). Each product
was sequenced and matched to NCBI database.2.4. Cell cultures
MH7A synovial cells isolated from intra-articular soft tissues of
the knee joints of RA patients were obtained from the Riken cell
bank (Ibaraki, Japan) through Dr. Ho-Geun Yoon of Yonsei University
(Seoul, Korea). Brieﬂy, MH7A is a cell line established by transfection
with the SV40 T antigen [30]. MH7A cells were cultured in RPMI-1640
(Gibco BRL, USA) supplemented with 10% heat-inactivated FBS,
penicillin (ﬁnal concentration, 100 U/ml), and streptomycin (ﬁnal
concentration, 0.1 mg/ml) at 37 °C in an atmosphere of 5% CO2 in air.
2.5. Measurement of hBAFF promoter activity
MH7A cells were transfected with pGL3-hBAFF-Luc and pcDNA–
lacZ for monitoring transfection efﬁciency by β-galactosidase assay.
Luciferase activity was determined by incubating cell extracts with
luciferase substrate (Promega). Luminescence was measured using
luminometer (Berthold Technologies, Oak Ridge, TN). Luciferase units
of experimental vector were normalized to the control vector in each
sample [28].
2.6. Hypoxia response element (HRE) reporter assay
HRE reporter plasmid 5× VEGF-HRE-Luc that was generated by clon-
ing ﬁve tandem couples of HRE derived from the human VEGF promoter
into the BglII site of pGL3 was kindly provided from Dr. Dong-Soo Im,
Korea Research Institute of Bioscience and Biotechnology (KRIBB)
(Taejeon, Korea) [31]. To measure the activity of VEGF transcription,
conﬂuent MH7A cells were transfected with VEGF-HRE-Luc plasmid
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) [32].
2.7. RT-PCR
MH7A cells were treated with TNF-α (20 ng/ml) for an appropriate
time. RNA was isolated from cells using TRIZOL (Invitrogen, Carlsbad,
CA). cDNA was synthesized from 1 μg of total RNA, using oligo dT18
primers and superscript reverse transcriptase in a ﬁnal volume of
21 μl (Bioneer, Taejeon, Korea). For standard PCR, one microliter of
the ﬁrst strand cDNA product was then used as a template for PCR
ampliﬁcation with Taq DNA polymerase (Bioneer, Taejeon, Korea).
PCR ampliﬁcation proceeded as follows: 35 thermocycles of 94 °C for
30 s, 55 °C for 30 s, and 72 °C for 30 s, using oligonucleotides speciﬁc
for hBAFF (forward: aat tca gag gaa gaa ggt cc; reverse: atg tga cat ctc
cat cca gt) and hGAPDH (forward: gaa ggt gaa ggt cgg agt c, reverse:
gaa gat ggt gat ggg att tc).
2.8. Western blot analysis
Cells were lysed in ice-cold lysis buffer containing 0.5% Nonidet
P-40 (vol/vol) in 20 mM Tris–HCl (pH 8.3); 150 mM NaCl; protease
inhibitors (2 μg/ml aprotinin, pepstatin, and chymostatin; 1 μg/ml
leupeptin and pepstatin; 1 mM phenylmethyl sulfonyl ﬂuoride
(PMSF); and 1 mM Na4VO3. Lysates were incubated for 30 min on
ice before centrifugation at 14,000 rpm for 5 min at 4 °C. Proteins
in the supernatant were denatured by boiling for 5 min in sodium
dodecyl sulfate (SDS) sample buffer. Proteins were separated by 12%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
nitrocellulose membranes. Following transfer, equal loading of pro-
tein was veriﬁed by Ponceau staining. The membranes were blocked
with 5% skim milk in Tris-buffered saline with Tween 20 (TBST)
(10 mM Tris–HCl, pH 7.6; 150 mM NaCl; 0.5% Tween 20) and incu-
bated with the indicated antibodies, monoclonal Myc (1:1000), tubu-
lin (1:5000), and polyclonal mouse BAFF (1:1000). Bound antibodies
were visualized with HRP-conjugated secondary antibodies with
the use of enhanced chemiluminescence (ECL) (Pierce, Rockford, IL).
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Experimental differences were tested for statistical signiﬁcance
using ANOVA and Student's t-test. p value of b0.05 or 0.01 was
considered to be signiﬁcant.
3. Results
3.1. Treatmentwith TNF-α increased hBAFF and hVEGF expression in RA-FLS
and MH7A cells
Given that FLS stimulated by abundant pro-inﬂammatory cyto-
kines increased VEGF and BAFF expression [2,6,7,19,20], we examined
whether BAFF expression could be associated with VEGF-mediated
angiogenesis in FLS. When FLS from RA patient were stimulated with
TNF-α for 6 h, hBAFF and hVEGF expressionwas increased signiﬁcant-
ly (Fig. 1A, C, and E). As shown in Fig. 1B, D, and F, hBAFF and hVEGF
expression was also increased by the stimulation of MH7A cells with
TNF-α for 6 h. It implicates that BAFF could be associated not only
with B cell survival but also VEGF expression in TNF-α-stimulated
synovial cells.
To conﬁrm the effect of TNF-α on hBAFF and VEGF expression, MH7A
cells were transfected with plasmids of pGL3-hBAFF-Luc or HRE–Luc. As
shown in Fig. 2A, hBAFF promoter activity as judged by luciferase activity
was increased by the stimulation with TNF-α for 6 h in MH7A cells,
dose-dependently. It was re-afﬁrmed by the measurement of hBAFF
transcript level in MH7A cells. hBAFF transcript levels were increased
by the stimulation with TNF-α for 12 h (Fig. 2B). In addition, VEGF–
HRE activity as judged by luciferase activity was enhanced by the stim-
ulation with TNF-α for 6 h (Fig. 2C). hVEGF transcript levels were also
increased by the stimulation with TNF-α for 12 h (Fig. 2D). It suggests
that BAFF may regulate VEGF expression, directly or indirectly.
3.2. VEGF expression in MH7A cells was dependent on hBAFF expression
To conﬁrm whether hVEGF expression is regulated by hBAFF,
changes in VEGF–HRE activity were measured in MH7A cells of0.25   0.5   1 0.25   0.5   1
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with BAFF–siRNA, VEGF–HRE activity as judged by luciferase activity
was inhibited by the stimulation with TNF-α for 6 h (Fig. 3A). We
also observed that no changes in cellular toxicity could be in BAFF–
siRNA-transfected cells as judged by trypan blue exclusion assay
(data not shown). Then, no differences were detected in total cell
number before and after transfection with BAFF–siRNA (Fig. 3B).
hBAFF and hVEGF transcript levels were decreased by BAFF–siRNA
in MH7A cells (Fig. 3C). Even though all of possible signal transduc-
tion on BAFF-mediated VEGF expression has not been cleared, it
suggests that hBAFF production could control VEGF expression in
synovial cells.3.3. c-Fos mediated TNF-α-induced hBAFF and VEGF expression in
MH7A cells
Given that hBAFF promoter could be regulated by c-Fos which consti-
tutes AP-1 [28] and AP-1 is one of nuclear targets to TNA-α-stimulated
signal transduction [33], we examined whether c-Fos could inﬂuence
TNF-α-mediated BAFF and VEGF expression in MH7A cells. Soluble(s)
form of hBAFF and c-Fos level was increased by TNF-α-stimulation
(Fig. 4A). To conﬁrm the effect of c-Fos on hBAFF and VEGF expression,
TNF-α-induced c-Fos expression was inhibited by c-fos-siRNA in MH7A
cells (Fig. 4B). Then, pGL3-hBAFF-Luc or VEGF–HRE-Luc was
co-transfected with c-fos-siRNA. As shown in Fig. 4C, hBAFF promoter
activity as judged by luciferase activity was decreased by the
co-transfection with c-fos-siRNA in MH7A cells. VEGF–HRE activity as
judged by luciferase activity was also reduced by the co-transfection
with c-fos-siRNA in MH7A cells (Fig. 4D). In addition, c-fos-siRNA re-
duced hBAFF and VEGF transcript level in MH7A cells (Fig. 4E). No
changes in cellular toxicity were found in c-fos-siRNA-transfected
cells (data not shown). This implicates that the c-Fos was translocated
into nucleus and could inﬂuence hBAFF promoter and VEGF–HRE,
resulting in hBAFF and VEGF gene expression, respectively. It suggests
that c-Fos could be a mediator in crosstalk between hBAFF expression
and VEGF expression in MH7A synovial cells (Fig. 5).N
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Bone and cartilage destruction in RA was mediated by the produc-
tion of destructive enzymes from FLS stimulated by abundant pro-
inﬂammatory cytokines such as IL-1, IL-6 and TNF-α [4,5]. Active
angiogenesis in RA synovium is facilitated by VEGF expression in
FLS, which recruit more inﬂammatory cells to synovitis sites [2,6,7].
RA is BAFF-associated autoimmune disorders [11,12]. BAFF produc-
tion in RA-FLS is associated with B cell survival [19,20]. We examined
whether BAFF expression could be associated with VEGF-mediated
angiogenesis in FLS. We observed that TNF-α increased hVEGF and
hBAFF expression (Figs. 1 and 2) and hVEGF expression was down-
regulated by hBAFF-siRNA (Fig. 3). It implicates that BAFF could beFig. 5. Possible crosstalk of BAFF production and VEGF expression in MH7A cells. Solid
lines represented that BAFF production should be increased by the stimulation with
TNF-α, which was mediated by c-Fos activation. Dotted lines represented that VEGF
expression might be dependent on c-Fos-mediated BAFF expression, which lead to
the angiogenesis in rheumatis arthritis (RA). c-Fos could be a mediator to bridge in
immune systems to control endothelial systems.a novel regulator to VEGF expression as well as anti-apoptotic mole-
cules to B cells.
Extensive studies showed that protein kinase C (PKC) may be a
molecular target for the treatment of many diseases [34–36]. PKC
activates expression of c-Fos, a member of the AP-1 family [37–39].
hBAFF promoter could be regulated by the up-regulation of ROS-
mediated c-Fos protein [28]. AP-1 is one of nuclear targets to the
signals generated by TNA-α-stimulation that inﬂuence the expression
of various genes [33]. So, we examined whether c-Fos could inﬂuence
TNF-α-mediated BAFF and VEGF expression in MH7A cells. Our
data showed that c-Fos-siRNA reduced hVEGF and BAFF expression
(Fig. 4). Data demonstrate that VEGF expression could be regulated
by c-Fos-mediated BAFF production. It suggests that c-Fos could
be a mediator to bridge in immune systems to control endothelial
systems (Fig. 5).
Overall, although all of possible signal transduction on TNF-α-
stimulated BAFF and BAFF-mediated VEGF expression by AP-1 activa-
tion in synoviocytes has not been cleared, this work suggests that
TNF-α-induced BAFF in synoviocytes could regulate VEGF expres-
sion through c-Fos activation. Data also suggest that TNF-α-induced
BAFF expression and BAFF-mediated VEGF expression in FLS may
crosstalk to maintain the capacity of such cells to protect B cells
from apoptosis and the supply of nutrients and oxygen in inﬂamma-
tory microenvironments. It may provide a novel approach to control
VEGF expression resulting in new blood vessel formation.Acknowledgments
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